Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Surface | 2 | 2014 | 112 | 0.790 |
Why?
|
| Dendritic Cells | 2 | 2014 | 436 | 0.660 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 500 | 0.650 |
Why?
|
| Hypersensitivity | 2 | 2023 | 226 | 0.590 |
Why?
|
| Asthma | 4 | 2026 | 920 | 0.560 |
Why?
|
| Allergens | 4 | 2025 | 344 | 0.540 |
Why?
|
| Antigens, CD1 | 2 | 2014 | 23 | 0.520 |
Why?
|
| Paramyxoviridae Infections | 2 | 2014 | 48 | 0.510 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 133 | 0.500 |
Why?
|
| Glycoproteins | 3 | 2025 | 344 | 0.490 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2014 | 396 | 0.370 |
Why?
|
| Peanut Hypersensitivity | 2 | 2025 | 88 | 0.360 |
Why?
|
| Cytokines | 3 | 2014 | 1332 | 0.340 |
Why?
|
| Lung Transplantation | 6 | 2011 | 360 | 0.310 |
Why?
|
| Epitopes | 2 | 2025 | 323 | 0.310 |
Why?
|
| Disease Management | 1 | 2014 | 556 | 0.310 |
Why?
|
| Antigens, Plant | 1 | 2025 | 35 | 0.220 |
Why?
|
| Arachis | 2 | 2025 | 76 | 0.220 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2024 | 6 | 0.220 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2024 | 8 | 0.220 |
Why?
|
| Thrombomodulin | 2 | 2014 | 18 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 5 | 2011 | 42 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 204 | 0.200 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 56 | 0.180 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 99 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 323 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 355 | 0.170 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2020 | 69 | 0.150 |
Why?
|
| Ganciclovir | 2 | 2008 | 101 | 0.140 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2017 | 32 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 126 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 324 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 221 | 0.120 |
Why?
|
| Respiratory Tract Infections | 2 | 2009 | 298 | 0.110 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 52 | 0.110 |
Why?
|
| Humans | 19 | 2026 | 130459 | 0.100 |
Why?
|
| Metapneumovirus | 1 | 2014 | 53 | 0.100 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 47 | 0.100 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 156 | 0.100 |
Why?
|
| Europe | 1 | 2014 | 363 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2014 | 238 | 0.090 |
Why?
|
| Adult | 8 | 2014 | 31103 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2008 | 805 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 765 | 0.090 |
Why?
|
| Immunoglobulin E | 2 | 2025 | 215 | 0.090 |
Why?
|
| Vaccination | 1 | 2017 | 1057 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2885 | 0.080 |
Why?
|
| Consensus | 1 | 2014 | 524 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 632 | 0.080 |
Why?
|
| Clarithromycin | 1 | 2011 | 133 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2014 | 384 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 643 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 24 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 16 | 0.080 |
Why?
|
| Child | 6 | 2025 | 26243 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2009 | 550 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 70 | 0.070 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 38 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 178 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1284 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1912 | 0.060 |
Why?
|
| Lung | 1 | 2014 | 1535 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2462 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 504 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2576 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3037 | 0.060 |
Why?
|
| 2S Albumins, Plant | 1 | 2025 | 6 | 0.060 |
Why?
|
| Skin Tests | 1 | 2025 | 100 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 29 | 0.050 |
Why?
|
| Pneumonia | 3 | 2014 | 340 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2009 | 3119 | 0.050 |
Why?
|
| Male | 8 | 2025 | 64573 | 0.040 |
Why?
|
| Adolescent | 5 | 2025 | 20875 | 0.040 |
Why?
|
| Female | 8 | 2025 | 70516 | 0.040 |
Why?
|
| Omalizumab | 1 | 2020 | 42 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2021 | 116 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2078 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1587 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 708 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 2289 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 33709 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2026 | 841 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 332 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 668 | 0.030 |
Why?
|
| United States | 1 | 2014 | 11994 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2025 | 15036 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1212 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 6176 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 567 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 5185 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1263 | 0.030 |
Why?
|
| Survival Rate | 2 | 2011 | 2110 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 978 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6421 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 226 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2014 | 173 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 979 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 609 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 5048 | 0.020 |
Why?
|
| Infant | 1 | 2025 | 13308 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 22 | 0.020 |
Why?
|
| Middle Aged | 4 | 2011 | 28393 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 71 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 1156 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 293 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2009 | 170 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 101 | 0.020 |
Why?
|
| Mycoses | 1 | 2009 | 110 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 330 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1068 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 371 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 252 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2009 | 17619 | 0.010 |
Why?
|
| Aged | 3 | 2009 | 20876 | 0.010 |
Why?
|
| Risk Factors | 2 | 2011 | 11007 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1479 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2008 | 397 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1605 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2009 | 1231 | 0.010 |
Why?
|
| Young Adult | 2 | 2009 | 10034 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4647 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1413 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 12838 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3338 | 0.010 |
Why?
|